These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 37042960)

  • 21. Equine Anti-SARS-CoV-2 Serum (ECIG) Binds to Mutated RBDs and N Proteins of Variants of Concern and Inhibits the Binding of RBDs to ACE-2 Receptor.
    Andrade SA; Batalha-Carvalho JV; Curi R; Wen FH; Covas DT; Chudzinski-Tavassi AM; Moro AM
    Front Immunol; 2022; 13():871874. PubMed ID: 35898497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epistasis at the SARS-CoV-2 Receptor-Binding Domain Interface and the Propitiously Boring Implications for Vaccine Escape.
    Rochman ND; Faure G; Wolf YI; Freddolino PL; Zhang F; Koonin EV
    mBio; 2022 Apr; 13(2):e0013522. PubMed ID: 35289643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repurposing antibiotics as potent multi-drug candidates for SARS-CoV-2 delta and omicron variants: molecular docking and dynamics.
    Serseg T; Linani A; Benarous K; Goumri-Said S
    J Biomol Struct Dyn; 2023 Dec; 41(20):10377-10387. PubMed ID: 36541102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics.
    Barton MI; MacGowan SA; Kutuzov MA; Dushek O; Barton GJ; van der Merwe PA
    Elife; 2021 Aug; 10():. PubMed ID: 34435953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of defensins as neutralizing agents against the deadly SARS-CoV-2.
    Deepthi V; Mohanakumar KP; Rajamma U
    J Biomol Struct Dyn; 2023 Apr; 41(7):2911-2925. PubMed ID: 35189779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV-2 variant surge and vaccine breakthrough infection: A computational analysis.
    Khater I; Nassar A
    Inform Med Unlocked; 2022; 29():100873. PubMed ID: 35136832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative Structural Analysis of Human ACE2 Receptor with Spike Protein of SARS-CoV-2 Variants: Implications to Understand Infectivity of the Virus.
    Koley T; Goswami A; Kumar M; Upadhyay N; Hariprasad G
    Adv Appl Bioinform Chem; 2022; 15():21-27. PubMed ID: 35734581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants.
    Chang MR; Ke H; Coherd CD; Wang Y; Mashima K; Kastrunes GM; Huang CY; Marasco WA
    EBioMedicine; 2022 Jun; 80():104025. PubMed ID: 35533497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Receptor binding domain of SARS-CoV-2 from Wuhan strain to Omicron B.1.1.529 attributes increased affinity to variable structures of human ACE2.
    Patil S; Alzahrani KJ; Banjer HJ; Halawani IF; Alzahrani H; Altayar MA; Albogami S; Angeles RF; Hassan AAA; Bhandi S; Raj AT
    J Infect Public Health; 2022 Jul; 15(7):781-787. PubMed ID: 35738053
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Rout J; Swain BC; Tripathy U
    J Biomol Struct Dyn; 2022 Feb; 40(2):860-874. PubMed ID: 32938313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathway enrichment analysis of virus-host interactome and prioritization of novel compounds targeting the spike glycoprotein receptor binding domain-human angiotensin-converting enzyme 2 interface to combat SARS-CoV-2.
    Gollapalli P; B S S; Rimac H; Patil P; Nalilu SK; Kandagalla S; Shetty P
    J Biomol Struct Dyn; 2022 Apr; 40(6):2701-2714. PubMed ID: 33146070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of mutations on RBD in the Spike protein of SARS-CoV-2 Alpha, Delta and Omicron variants.
    da Costa CHS; de Freitas CAB; Alves CN; Lameira J
    Sci Rep; 2022 May; 12(1):8540. PubMed ID: 35595778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design of a bifunctional pan-sarbecovirus entry inhibitor targeting the cell receptor and viral fusion protein.
    Jin H; Cheng L; Gong Y; Zhu Y; Chong H; Zhang Z; He Y
    J Virol; 2023 Aug; 97(8):e0019223. PubMed ID: 37578234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
    Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
    BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of mutation on structure, function and dynamics of receptor binding domain of human SARS-CoV-2 with host cell receptor ACE2: a molecular dynamics simulations study.
    Dehury B; Raina V; Misra N; Suar M
    J Biomol Struct Dyn; 2021 Nov; 39(18):7231-7245. PubMed ID: 32762417
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Arumugam M; Shanmugavel B; Sellppan M; Pavadai P
    J Biomol Struct Dyn; 2024; 42(2):1072-1078. PubMed ID: 37139540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urtica dioica agglutinin (UDA) as a potential candidate for inhibition of SARS-CoV-2 Omicron variants: In silico prediction and experimental validation.
    Sabzian-Molaei F; Hosseini S; Alipour A; Ghaderi H; Fotouhi-Chahouki F; Hadi A; Shahsavarani H
    Phytomedicine; 2023 Mar; 111():154648. PubMed ID: 36681052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vitamin D3 and its hydroxyderivatives as promising drugs against COVID-19: a computational study.
    Song Y; Qayyum S; Greer RA; Slominski RM; Raman C; Slominski AT; Song Y
    J Biomol Struct Dyn; 2022; 40(22):11594-11610. PubMed ID: 34415218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.